Abliva’s CEO about the phase II study
In December last year, Abliva initiated a potentially pivotal phase II study with KL1333. The candidate is being developed for the treatment of primary mitochondrial disease in adults, a group of rare diseases that lack effective treatment. CEO Ellen K. Donnelly visited BioStock’s studio to tell us more.
See the interview with Abliva’s CEO Ellen K. Donnelly, in English, below.
See Ellen K.Donnelly present Abliva at BioStock Investor Meeting here:
